The Company’s preliminary full year 2023 revenue results represent growth of over 10% in core revenue driven by over 40% growth in instrument revenue, in each case as compared with 2022.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LAB:
- Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue
- Standard BioTools trading halted, news dissemination
- Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools
- Standard BioTools completes merger with SomaLogic
- SomaLogic shareholders approve transaction with Standard BioTools
